Evaluation of topical povidone-iodine in chronic suppurative otitis media.
OBJECTIVE
To evaluate if povidone-iodine (PVP-I) can be used topically in the treatment of chronic suppurative otitis media-tubotympanic disease and to compare it with ciprofloxacin hydrochloride ear drops.


METHODS
Prospective double-blind randomized study.


METHODS
Academic tertiary medical center.


METHODS
Forty patients with chronic suppurative otitis media were randomized into 2 groups.


METHODS
One group (19 patients) received 5% PVP-I ear drops, while the other group (21 patients) received 0.3% ciprofloxacin ear drops. Both were administered topically, 3 drops 3 times daily for 10 days. These patients were followed up at weekly intervals for up to 4 weeks after commencing therapy.


RESULTS
Clinical improvement at the end of study was 88% in the PVP-I group and 90% in the ciprofloxacin group. The most commonly isolated organism was Pseudomonas aeruginosa. In vitro resistance to ciprofloxacin was seen in 17% of organisms, while no resistance was seen for PVP-I.


CONCLUSIONS
To our knowledge, this is the first study to evaluate the efficacy of PVP-I as a topical agent in the treatment of chronic suppurative otitis media. The results show that clinically, topical PVP-I is as effective as topical ciprofloxacin, with a superior advantage of having no in vitro drug resistance. Also, there is an added benefit of reduced cost of therapy.
Jaya
C
C
Department of Otorhinolaryngology and Head and Neck Surgery, Christian Medical College, Vellore, India.
Job
Anand
A
Mathai
Elizabeth
E
Antonisamy
B
B
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D002648:Child; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000008:administration & dosage*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage*; D008297:Male; D010035:Otitis Media, Suppurative / Q000150:complications / Q000188:drug therapy*; D011206:Povidone-Iodine / Q000008:administration & dosage*; D011446:Prospective Studies; D018058:Tympanic Membrane Perforation / Q000150:complications / Q000188:drug therapy*
D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; C474742:ciprofloxacin, hydrocortisone drug combination; D002939:Ciprofloxacin; D011206:Povidone-Iodine; D006854:Hydrocortisone